Arvinas (ARVN) news

Arvinas: Phase 1 ARV-102 showed dose-dependent improvements in eye movement in Parkinson's patients

Arvinas Inc. (ARVN) has reported preliminary findings from its Phase 1 clinical trial of ARV-102, an investigational therapy targeting Parkinson’s disease. The data indicate dose-dependent improvements in eye movement among participants, a key biomarker associated with the condition. These results,…

Arvinas: Findings support evaluation of ARV-102 as a therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation

Arvinas, Inc. (Nasdaq: ARVN) continues to advance its pipeline of investigational therapies based on its proprietary PROTAC (PROteolysis TArgeting Chimera) platform. One of its key programs, ARV-102, is an orally bioavailable PROTAC designed to target and degrade leucine-rich repeat kinase 2…

Arvinas shares novel oculomotor and biomarker data from phase 1 clinical trial of ARV-102 in patients with Parkinson’s disease

Arvinas, Inc. (Nasdaq: ARVN) announced that novel oculomotor and biomarker data from the Phase 1 clinical trial of its investigational drug ARV-102 in patients with Parkinson’s disease will be presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Seoul,…

Arvinas announces first patient dosed in phase 1/2 clinical trial of ARV-6723, the company’s first immuno-oncology candidate

US FDA - Authorizes Guardant360 CDX assay as companion diagnostic for breast cancer

The U.S. Food and Drug Administration (FDA) has authorized the Guardant360® CDx liquid biopsy test as a companion diagnostic for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic…